title: Significance of serum matrix metalloproteinases and their inhibitors on the antifibrogenetic effect of interferon-alfa in chronic hepatitis C patients.
abstract: OBJECTIVE
  The imbalance between matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) is considered to be an important determination of deposition and breakdown of the extracellular matrix. To investigate the antifibrogenetic effect of interferon-alpha (IFN-alpha) treatment on factors regulating hepatic fibrosis, serum MMP-1, MMP-2, TIMP-1 and TIMP-2 levels were measured by the one-step sandwich enzyme immunoassay in 27 patients with chronic hepatitis C and compared with the histological status of the patients before and at the end of treatment.
  
  
  RESULTS
  After 6 months of IFN-alpha treatment, the histological status of liver fibrosis showed improvement in 9 patients (IF group) and no change or a worsening in 18 patients (NIF group). Compared with pretreatment levels, in the IF group, IFN treatment caused a significant increase in the MMP-1/TIMP-1 ratio. In the NIF group, however, the MMP-1/TIMP-1 ratio tended towards a decrease; moreover, there was not only a significant increase in TIMP-2 levels but also a tendency towards an increase in TIMP-1 levels.
  
  
  CONCLUSIONS
  These results suggested that an elevated MMP-1/TIMP-1 ratio may ameliorate liver fibrosis by interferon in cases of chronic hepatitis C, whereas elevated levels of TIMP-1 and TIMP-2 might impede improvement.
authors.affiliation: Second Department of Internal Medicine, Kobe University School of Medicine, Kobe, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Ninomiya
authors.forename: S
authors.initials: S
authors.lastname: Yoon
authors.forename: H
authors.initials: H
authors.lastname: Nagano
authors.forename: Y
authors.initials: Y
authors.lastname: Kumon
authors.forename: Y
authors.initials: Y
authors.lastname: Seo
authors.forename: M
authors.initials: M
authors.lastname: Kasuga
authors.forename: Y
authors.initials: Y
authors.lastname: Yano
authors.forename: M
authors.initials: M
authors.lastname: Nakaji
authors.forename: Y
authors.initials: Y
authors.lastname: Hayashi
mesh_terms: D000933:Antifibrinolytic Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D005260:Female; D019698:Hepatitis C, Chronic / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007273:Injections, Intramuscular; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D020781:Matrix Metalloproteinase 1 / Q000097:blood; D020778:Matrix Metalloproteinase 2 / Q000097:blood; D061965:Matrix Metalloproteinase Inhibitors; D020782:Matrix Metalloproteinases / Q000097:blood*; D008875:Middle Aged; D011480:Protease Inhibitors / Q000097:blood*; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000097:blood; D019716:Tissue Inhibitor of Metalloproteinase-2 / Q000097:blood
chemical_list: D000933:Antifibrinolytic Agents; D015415:Biomarkers; D016898:Interferon-alpha; D061965:Matrix Metalloproteinase Inhibitors; D011480:Protease Inhibitors; D019715:Tissue Inhibitor of Metalloproteinase-1; D019716:Tissue Inhibitor of Metalloproteinase-2; D020782:Matrix Metalloproteinases; D020778:Matrix Metalloproteinase 2; D020781:Matrix Metalloproteinase 1